To date, (–)-parthenolide, which also has the moiety of active exo-methylene lactone (Figure 1A, (–)-xanthatin), is one of the molecules that has been established to selectively target human acute myelogenous leukemia stem cells; mechanistically, (–)-parthenolide is known to utilize NF-κB inhibition and ROS production [37]. Here, NFKB1 is linked to acute myeloid leukemia.